Primary prevention of congenital anomalies: Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases

Domenica Taruscio, Francesca Baldi, Pietro Carbone, Amanda J. Neville, Giovanni Rezza, Caterina Rizzo, Alberto Mantovani

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Congenital anomalies (CA) represent an important fraction of rare diseases, due to the critical role of non-genetic factors in their pathogenesis. CA are the main group of rare diseases in which primary prevention measures will have a beneficial impact. Indeed, since 2013 the European Union has endorsed a body of evidence-based recommendations for CA primary prevention; the recommendations aim at facilitating the inclusion of primary prevention actions the National Rare Disease Plans of EU Member States and encompass different public health fields, from environment through to maternal diseases and lifestyles. The chapter overviews and discusses the assessment of main risk factors for CA, such as environmental toxicants, maternal health and lifestyles and infections, with a special attention to issues that are emerging or need more knowledge. Overall, the availability of CA registries is important for estimating the health burden of CA, identifying possible hotspots, assessing the impact of interventions and addressing further, fit-to-purpose research. The integration of relevant public health actions that are already in place (e.g., control of noxious chemicals, vaccination programmes, public health services addressing chronic maternal conditions) can increase the affordability and sustainability of CA primary prevention. In developing countries with less primary prevention in place and limited overall resources, a first recognition phase may be pivotal in order to identify priority targets. In the meanwhile, policy makers should be made aware that primary prevention of RD supports publicly endorsed societal values like the knowledge-based promotion of health, empowerment, equity and social inclusiveness.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages301-322
Number of pages22
DOIs
Publication statusPublished - Jan 1 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1031
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Primary Prevention
Health Services
Communicable Diseases
Public health
Health
Rare Diseases
Life Style
Environment and Public Health
Mothers
Developing countries
Sustainable development
United States Public Health Service
Availability
European Union
Health Promotion
Administrative Personnel
Developing Countries
Registries
Maternal Health
Vaccination

Keywords

  • Congenital anomalies
  • Environmental chemicals
  • Health services
  • Infectious diseases
  • Maternal health
  • Primary prevention

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Taruscio, D., Baldi, F., Carbone, P., Neville, A. J., Rezza, G., Rizzo, C., & Mantovani, A. (2017). Primary prevention of congenital anomalies: Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases. In Advances in Experimental Medicine and Biology (pp. 301-322). (Advances in Experimental Medicine and Biology; Vol. 1031). Springer New York LLC. https://doi.org/10.1007/978-3-319-67144-4_18

Primary prevention of congenital anomalies : Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases. / Taruscio, Domenica; Baldi, Francesca; Carbone, Pietro; Neville, Amanda J.; Rezza, Giovanni; Rizzo, Caterina; Mantovani, Alberto.

Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. p. 301-322 (Advances in Experimental Medicine and Biology; Vol. 1031).

Research output: Chapter in Book/Report/Conference proceedingChapter

Taruscio, D, Baldi, F, Carbone, P, Neville, AJ, Rezza, G, Rizzo, C & Mantovani, A 2017, Primary prevention of congenital anomalies: Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases. in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1031, Springer New York LLC, pp. 301-322. https://doi.org/10.1007/978-3-319-67144-4_18
Taruscio D, Baldi F, Carbone P, Neville AJ, Rezza G, Rizzo C et al. Primary prevention of congenital anomalies: Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases. In Advances in Experimental Medicine and Biology. Springer New York LLC. 2017. p. 301-322. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-67144-4_18
Taruscio, Domenica ; Baldi, Francesca ; Carbone, Pietro ; Neville, Amanda J. ; Rezza, Giovanni ; Rizzo, Caterina ; Mantovani, Alberto. / Primary prevention of congenital anomalies : Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases. Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. pp. 301-322 (Advances in Experimental Medicine and Biology).
@inbook{3404cffc36c1488ca3257f802ef750cd,
title = "Primary prevention of congenital anomalies: Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases",
abstract = "Congenital anomalies (CA) represent an important fraction of rare diseases, due to the critical role of non-genetic factors in their pathogenesis. CA are the main group of rare diseases in which primary prevention measures will have a beneficial impact. Indeed, since 2013 the European Union has endorsed a body of evidence-based recommendations for CA primary prevention; the recommendations aim at facilitating the inclusion of primary prevention actions the National Rare Disease Plans of EU Member States and encompass different public health fields, from environment through to maternal diseases and lifestyles. The chapter overviews and discusses the assessment of main risk factors for CA, such as environmental toxicants, maternal health and lifestyles and infections, with a special attention to issues that are emerging or need more knowledge. Overall, the availability of CA registries is important for estimating the health burden of CA, identifying possible hotspots, assessing the impact of interventions and addressing further, fit-to-purpose research. The integration of relevant public health actions that are already in place (e.g., control of noxious chemicals, vaccination programmes, public health services addressing chronic maternal conditions) can increase the affordability and sustainability of CA primary prevention. In developing countries with less primary prevention in place and limited overall resources, a first recognition phase may be pivotal in order to identify priority targets. In the meanwhile, policy makers should be made aware that primary prevention of RD supports publicly endorsed societal values like the knowledge-based promotion of health, empowerment, equity and social inclusiveness.",
keywords = "Congenital anomalies, Environmental chemicals, Health services, Infectious diseases, Maternal health, Primary prevention",
author = "Domenica Taruscio and Francesca Baldi and Pietro Carbone and Neville, {Amanda J.} and Giovanni Rezza and Caterina Rizzo and Alberto Mantovani",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-67144-4_18",
language = "English",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "301--322",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Primary prevention of congenital anomalies

T2 - Special focus on environmental chemicals and other toxicants, maternal health and health services and infectious diseases

AU - Taruscio, Domenica

AU - Baldi, Francesca

AU - Carbone, Pietro

AU - Neville, Amanda J.

AU - Rezza, Giovanni

AU - Rizzo, Caterina

AU - Mantovani, Alberto

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Congenital anomalies (CA) represent an important fraction of rare diseases, due to the critical role of non-genetic factors in their pathogenesis. CA are the main group of rare diseases in which primary prevention measures will have a beneficial impact. Indeed, since 2013 the European Union has endorsed a body of evidence-based recommendations for CA primary prevention; the recommendations aim at facilitating the inclusion of primary prevention actions the National Rare Disease Plans of EU Member States and encompass different public health fields, from environment through to maternal diseases and lifestyles. The chapter overviews and discusses the assessment of main risk factors for CA, such as environmental toxicants, maternal health and lifestyles and infections, with a special attention to issues that are emerging or need more knowledge. Overall, the availability of CA registries is important for estimating the health burden of CA, identifying possible hotspots, assessing the impact of interventions and addressing further, fit-to-purpose research. The integration of relevant public health actions that are already in place (e.g., control of noxious chemicals, vaccination programmes, public health services addressing chronic maternal conditions) can increase the affordability and sustainability of CA primary prevention. In developing countries with less primary prevention in place and limited overall resources, a first recognition phase may be pivotal in order to identify priority targets. In the meanwhile, policy makers should be made aware that primary prevention of RD supports publicly endorsed societal values like the knowledge-based promotion of health, empowerment, equity and social inclusiveness.

AB - Congenital anomalies (CA) represent an important fraction of rare diseases, due to the critical role of non-genetic factors in their pathogenesis. CA are the main group of rare diseases in which primary prevention measures will have a beneficial impact. Indeed, since 2013 the European Union has endorsed a body of evidence-based recommendations for CA primary prevention; the recommendations aim at facilitating the inclusion of primary prevention actions the National Rare Disease Plans of EU Member States and encompass different public health fields, from environment through to maternal diseases and lifestyles. The chapter overviews and discusses the assessment of main risk factors for CA, such as environmental toxicants, maternal health and lifestyles and infections, with a special attention to issues that are emerging or need more knowledge. Overall, the availability of CA registries is important for estimating the health burden of CA, identifying possible hotspots, assessing the impact of interventions and addressing further, fit-to-purpose research. The integration of relevant public health actions that are already in place (e.g., control of noxious chemicals, vaccination programmes, public health services addressing chronic maternal conditions) can increase the affordability and sustainability of CA primary prevention. In developing countries with less primary prevention in place and limited overall resources, a first recognition phase may be pivotal in order to identify priority targets. In the meanwhile, policy makers should be made aware that primary prevention of RD supports publicly endorsed societal values like the knowledge-based promotion of health, empowerment, equity and social inclusiveness.

KW - Congenital anomalies

KW - Environmental chemicals

KW - Health services

KW - Infectious diseases

KW - Maternal health

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=85037672833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037672833&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-67144-4_18

DO - 10.1007/978-3-319-67144-4_18

M3 - Chapter

AN - SCOPUS:85037672833

T3 - Advances in Experimental Medicine and Biology

SP - 301

EP - 322

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -